Opinion

Video

Long-Term Use of FM Treatments

Experts discuss the long-term safety and efficacy of agents used for the treatment of fibromyalgia (FM).

Transcript

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP: What do we know about the long-term use of milnacipran, duloxetine, pregabalin in patients with fibromyalgia? Is there any evidence of tolerance, adverse events improvement? Anything long-term that we know.

Daniel Clauw, MD: All the drugs to get approved had to have one year open labeled extension. We have that much data, but not more than a year. And even though it was only 1,000 or 1,500 patients that got exposed for a year. After that, it's just like the regular surveillance system, which is not very good at telling us if there are long-term adverse effects for people taking these drugs for decades.

Benjamin Natelson, MD: For lack of efficacy. That's another issue. I seem to remember, although I couldn't cite it, there was a paper that was talking about these treatments and having a relatively short I guess as you pointed out, Dan, they have to have worked for a year, what's your experience, Wendy and you also Dr Botsoglou on long term adverse effects.

Kostas Botsoglou, MD: I've seen tolerance with some of these patients where they've been on it for quite a while and they just keep getting more breakthrough pain and so forth but in terms of safety, I haven't seen any new safety signals, we are doing chemistries and kidney functions and liver functions in these patients routinely anyway. It's more the tolerance that's the issue.

Wendy Wright, DNP, ANP-BC, FNP-BC, FAANP, FAAN, FNAP: I agree with you, and we've seen that for years with SSRIs and tolerance. Part of me wonders is the condition worsening and that's why they're feeling or are they developing a tolerance? Certainly, with opioids we start to see Hy Opioid hyperalgesia and that's a real issue as well. But I don't know of any safety issues when these products are used long term.

Transcript edited for clarity.

Related Videos
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
© 2024 MJH Life Sciences

All rights reserved.